Big pharma appointments to PhRMA Board
pharmafile | April 15, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Big Pharma, Celgene, Merck, Pfizer, PhRMA
Chairman and chief executive of Celgene Robert Hugin has been elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Also elected were Pfizer’s president and chief executive Ian Read, as chairman-elect of the PhRMA Board of directors, and Kenneth Frazier, chairman, president and chief executive of Merck, as Board treasurer.
Hugin became chief executive of Celgene in June of 2010 having served as president and chief operating officer since May 2006. In June 2011, Celgene’s Board elected him as chairman.
He joined Celgene as senior vice president and chief financial officer in June 1999 and was elected to the Board of directors in December 2001.
“I look forward to working with our leadership team, the PhRMA staff, and our member companies to advocate for policies that support the advancement of medical innovation and that ensure access for patients to life-extending therapies,” Hugin said.
Read is the chairman and chief executive of Pfizer. He began his career there in 1978 as an operational auditor. Read worked in Latin America through 1995, holding positions in a number of Pfizer’s international operations.
In 1996, he was appointed president of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became executive vice president, Europe in 2000, and was named a corporate vice president in 2001. In 2006, he became senior vice president, Pfizer, and group president of the Worldwide Biopharmaceutical Businesses.
Read said: “PhRMA is committed to working with policymakers, elected officials and our members to develop the right policy framework that supports innovation that results in creating value for society by enhancing productivity and improving the quality of life globally.”
Frazier is chairman, president and chief executive of Merck. Previously, he served as president of Merck with responsibility for the company’s three major divisions: Global Human Health, Merck’s sales and marketing division for pharmaceutical and vaccine products; Merck Manufacturing, the company’s manufacturing and supply division; and Merck Research Laboratories, Merck’s research organisation.
“Congratulations to my colleagues who have made many outstanding contributions to healthcare and our industry through their work with PhRMA. I look forward to continuing my work with PhRMA to ensure that patients and caregivers benefit from the many scientific advances that the pharmaceutical industry has to offer,” said Frazier.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
